gadolinium has been researched along with Chronic Progressive Multiple Sclerosis in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (57.14) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, DL; Collins, DL; Dadar, M; Mahmoud, S; Maranzano, J; Narayanan, S | 1 |
| Christine, LF; Grouin, JM; Kobelt, G; Labauge, P; Laplaud, D; Lotz, M; Manchon, E; Moreau, T; Pau, D; Vukusic, S | 1 |
| Cutter, G; Koch, MW; Mostert, J; Uitdehaag, B | 1 |
| Arnold, DL; Barkhof, F; Belachew, S; Bernasconi, C; Elliott, C; Hauser, SL; Kappos, L; Wei, W; Wolinsky, JS | 1 |
| Aguglia, U; Amato, MP; Carreras, E; Currò, D; Di Bartolomeo, P; Di Gioia, M; Donelli, A; Farge, D; Filippi, M; Gualandi, F; Iacopino, P; Lugaresi, A; Mancardi, GL; Massacesi, L; Merelli, E; Rambaldi, A; Roccatagliata, L; Rottoli, MR; Saccardi, R; Saiz, A; Sormani, MP; Vuolo, L | 1 |
| Bowen, JD; Carpenter, A; Corboy, JR; Fischkoff, SA; Freedman, MS; Hariri, RJ; Huddlestone, J; Kremenchutzky, M; Krupp, L; Lublin, FD; Paulo, C | 1 |
| Axelsson, M; Blennow, K; Burman, J; Malmeström, C; Raininko, R; Zetterberg, H | 1 |
| Daumer, M; Ebers, GC; Hintzen, R; Morrissey, S; Neuhaus, A | 1 |
| Koch-Henriksen, N | 1 |
| Aufauvre, D; Camu, W; Chanalet, S; Clavelou, P; Cohen, M; Filleau-Bertogliatti, C; Lebrun, C; Malandain, G; Thomas, P | 1 |
| Aghsaie, A; Alikhani, K; Bonab, MM; Gheini, MR; Harirchian, MH; Hosseinian, SM; Jafarian, S; Karvigh, SA; Khorramnia, S; Lotfi, J; Moghadam, NB; Motamed, MR; Nikbin, B; Sahraian, MA; Togha, M; Yadegari, S | 1 |
| Bacchetti, P; Bostrom, A; Goodkin, D; Hietpas, J; Leppert, D; Lindberg, R; Waubant, E | 1 |
| Barkhof, F; Eikelenboom, MJ; Giovannoni, G; Lazeron, RH; Petzold, A; Polman, CH; Sharief, M; Silber, E; Thompson, EJ; Uitdehaag, BM | 1 |
| Hughes, RA | 1 |
| Miller, A; Panitch, H; Paty, D; Weinshenker, B | 1 |
| Braga, FT; da Rocha, AJ; da Silva, CJ; Maia, AC; Mendes, MF; Tilbery, CP | 1 |
| Nadeau, SE | 1 |
| Dastidar, P; Elovaara, I; Lehtimäki, T; Leppäkynnäs, M; Luomala, M; Peltola, J; Ukkonen, M | 1 |
| Barkhof, F; Brex, P; Filippi, M; Hahn, D; Kappos, L; Miller, DH; Polman, CH; Pozzilli, C; Thompson, AJ; van Waesberghe, JH; Yousry, T | 1 |
| Filippi, M; Gualandi, F; Inglese, M; Lugaresi, A; Mancardi, GL; Marmont, A; Marrosu, MG; Massacesi, L; Meucci, G; Murialdo, A; Pagliai, F; Saccardi, R; Sardanelli, F; Sormani, MP | 1 |
| Hooper, DC; Koprowskil, H; Leist, T; Mikheeva, T; Spitsin, S; Streletz, LJ | 1 |
2 review(s) available for gadolinium and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Topics: Adult; Gadolinium; Humans; Immunologic Factors; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Patient Reported Outcome Measures; Quality of Life; Recurrence | 2022 |
Interferon beta 1a for secondary progressive multiple sclerosis.
Topics: Clinical Trials as Topic; Disability Evaluation; Disease Progression; Gadolinium; Humans; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Chronic Progressive; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
11 trial(s) available for gadolinium and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.
Topics: Adult; Antineoplastic Agents; Female; Gadolinium; Hematopoietic Stem Cell Transplantation; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2015 |
Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Topics: Adult; Brain; Canada; Contrast Media; Disability Evaluation; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Mesenchymal Stem Cell Transplantation; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Severity of Illness Index; Treatment Outcome; United States | 2014 |
Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study.
Topics: Adult; Autoantigens; Disease Progression; Disease-Free Survival; Drug Resistance; Female; Fever; Follow-Up Studies; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Mesenchymal Stem Cell Transplantation; Multiple Sclerosis, Chronic Progressive; Postoperative Nausea and Vomiting; Transplantation, Autologous; Treatment Outcome | 2012 |
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Topics: Disease Progression; Double-Blind Method; Female; Gadolinium; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Multiple Sclerosis, Chronic Progressive; Predictive Value of Tests; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2003 |
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.
Topics: Adult; Autoantibodies; Biomarkers; Brain; Brain Diseases; Disease Progression; Female; Gadolinium; Humans; Immunoglobulin G; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neurofilament Proteins; Predictive Value of Tests | 2003 |
Interferon beta 1a for secondary progressive multiple sclerosis.
Topics: Clinical Trials as Topic; Disability Evaluation; Disease Progression; Gadolinium; Humans; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Chronic Progressive; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Topics: Brain; Contrast Media; Depression; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Gadolinium; Humans; Immunologic Factors; Injections, Subcutaneous; Interferon beta-1b; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neutralization Tests; Outcome Assessment, Health Care; Quality of Life; Severity of Illness Index | 2004 |
Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
Topics: Adult; Atrophy; Brain; Cell Adhesion Molecules; E-Selectin; Enzyme-Linked Immunosorbent Assay; Female; Gadolinium; Humans; Immunohistochemistry; Inflammation; Injections, Intravenous; Integrin alpha4beta1; Integrins; Intercellular Adhesion Molecule-1; Lymphocyte Function-Associated Antigen-1; Lymphocytes; Magnetic Resonance Imaging; Male; Methylprednisolone Hemisuccinate; Middle Aged; Monocytes; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Predictive Value of Tests; Receptors, Lymphocyte Homing; Vascular Cell Adhesion Molecule-1 | 2000 |
T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
Topics: Adult; Axons; Disease Progression; Europe; Female; Gadolinium; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Chronic Progressive; Severity of Illness Index; Treatment Outcome | 2001 |
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Gadolinium; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Preoperative Care; Transplantation, Autologous; Treatment Outcome | 2001 |
Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease.
Topics: Administration, Oral; Adult; Female; Gadolinium; Humans; Inosine; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Peroxynitrous Acid; Uric Acid | 2001 |
9 other study(ies) available for gadolinium and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation.
Topics: Brain; Contrast Media; Gadolinium; Humans; Inflammation; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; White Matter | 2022 |
Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets.
Topics: Contrast Media; Disability Evaluation; Gadolinium; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Outcome Assessment, Health Care; Walking | 2020 |
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Topics: Adult; Brain; Contrast Media; Disease Progression; Female; Gadolinium; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; White Matter | 2019 |
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.
Topics: Adipokines; Adult; Aged; Astrocytes; Brain; Chitinase-3-Like Protein 1; Cohort Studies; Disability Evaluation; Female; Gadolinium; Glial Fibrillary Acidic Protein; Humans; Lectins; Lipopolysaccharide Receptors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive | 2016 |
MRI as an outcome in multiple sclerosis clinical trials.
Topics: Adult; Cross-Sectional Studies; Disability Evaluation; Gadolinium; Humans; Image Enhancement; Longitudinal Studies; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic | 2009 |
No shortcuts to outcome in MS clinical trials?
Topics: Gadolinium; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
[Longitudinal study of health related quality of life in multiple sclerosis: correlation with MRI parameters].
Topics: Adolescent; Adult; Atrophy; Brain; Cognition; Contrast Media; Disease Progression; Female; Gadolinium; Humans; Image Processing, Computer-Assisted; Interferon Type I; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuropsychological Tests; Quality of Life; Recombinant Proteins; Young Adult | 2010 |
Trigeminal involvement in multiple sclerosis: magnetic resonance imaging findings with clinical correlation in a series of patients.
Topics: Adult; Female; Gadolinium; Humans; Hypertrophy; Incidence; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myelin Sheath; Pons; Trigeminal Nerve; Trigeminal Neuralgia | 2005 |
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Topics: Adult; Brain; Contrast Media; Disease Progression; Gadolinium; Humans; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Randomized Controlled Trials as Topic; Research Design; Treatment Failure | 2006 |